Clinical Trial

Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants. This study will also assess the safety and tolerability when vimseltinib is co-administered with the clinical OCT2 substrate (metformin) in healthy male participants. This study will last approximately 25 days.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-08-28; most recent amendment 2026-02-09.
Status change: Active, Not Recruiting → Completed 2026-02-09
Status change: Recruiting → Active, Not Recruiting 2026-01-08
Status change: Not Yet Recruiting → Recruiting 2025-11-03
Trial Details
NCT Number NCT07158411
Lead Sponsor Deciphera Pharmaceuticals, LLC
Conditions Healthy Participants
Enrollment 22 participants
Start Date 2025-11-20
Primary Completion 2026-01-30 (estimated)
Study Completion 2026-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-11